Manifest2 - A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

Project: Research

Project Details

StatusActive
Effective start/end date24/06/21 → 23/06/26

Keywords

  • phase 3 study
  • treatment safety
  • treatment effficacy
  • Myelofibrosis